Drug Detail

Information about Gleevec + AT13387

Generic Name	Imatinib + AT13387
IND	STI571 + AT13387
Brand Name (US)	Gleevec + AT13387
Manufacturer	Astex Therapeutics
Drug Type	HSP90 Inhibitor
Delivery	Oral + Intravenous
Approval Status	Gleevec is approved for GIST. This combination is in a phase 1/2 trial for GIST.
Indications
Overall Strategy
Strategy
Drug Category	KIT/PDGFRA inhibitor + HSP90 inhibitor

AT13387 is a HSP90 inhibitor. This combination is the first HSP90 inhibitor/Gleevec combination to be evaluated in GIST.

Links
	AT13387 in LRG drug database

	The HSP90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models

	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models.

Trials of this drug
	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Trial results
	Phase 2 Dose escalation Study EJC 2016

	2013 - GI ASCO abstract - Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST).